FDA grants orphan-drug status to ZIOPHARM cancer drug

05/11/2008 | Forbes

The FDA has granted ZIOPHARM Oncology orphan-drug status for Palifosfamide, a treatment for soft-tissue sarcoma. The injectable form of the drug is currently in Phase II trials, while Phase I studies for an oral formulation are expected to begin in early 2009.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA